Histone demethylase inhibitors were initially developed in an attempt to address decreased methylation in pediatric K27M gliomas, and the broad demethylase inhibitor JIB 04 shows promising synergy with TMZ and counteracts TMZ resistance in GBM cells in vitro [139]. The gene discussed is MBD2; the disease is central nervous system cancer.